Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | MRD highlights from the IMW meeting

Natalie Callander, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, gives an overview of key updates on the use of measurable residual disease (MRD) in the field of multiple myeloma, as presented at the 18th International Myeloma Workshop (IMW 2021) congress. Dr Callander highlights data from trials such as the MYELOMA XI trial (NCT01554852) which is presenting novel data on MRD, the CC-220-MM-001 trial (NCT02773030) exploring different combinations with iberdomide, and a real-world data study of treatment pathways for patients with multiple myeloma in France. Dr Callander also talks about studies comparing bone marrow plasma cells with circulating tumor cells. Additionally, Dr Callander talks on updates from chimeric antigen receptor (CAR) T-cell therapy studies such as the CARTITUDE-1 (NCT03548207) and CARTITUDE-2 (NCT04133636) trials which will be presented at the meeting. This interview took place during the IMW 2021 congress.